000739:SHE
Apeloa Pharmaceutical Co Ltd
23,42 CN¥
arrow_downward
-1,64%(-0,39) 1D
16-окт., 15:04:48 GMT+8 · CNY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 000739...
Open
24,04 CN¥
High
24,76 CN¥
Low
23,09 CN¥
Mkt. cap
27,13 млд
Avg. vol.
16,27 млн
Volume
15,09 млн
Dividend
1,61%
Quarterly dividend
0,09 CN¥
Ex-dividend date
2026-ж., 8-окт.
P/E ratio
31,78
52-wk high
28,50 CN¥
52-wk low
14,89 CN¥
EPS
0,74 CN¥
Shares outstanding
1,16 млд
No. of employees
7 миң
Open
24,04 CN¥
High
24,76 CN¥
Low
23,09 CN¥
Mkt. cap
27,13 млд
Avg. vol.
16,27 млн
Volume
15,09 млн
Dividend
1,61%
Quarterly dividend
0,09 CN¥
Ex-dividend date
2026-ж., 8-окт.
P/E ratio
31,78
52-wk high
28,50 CN¥
52-wk low
14,89 CN¥
EPS
0,74 CN¥
Shares outstanding
1,16 млд
No. of employees
7 миң
News stories
From web sources and news partners
Business Wire
·
39 мүнөт мурун
Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: FFR to Hold Listing Ceremony and First Investor Day at the Nasdaq Tower on Oct. 26; Three New Robotics Product Offerings Launched
TradingView
·
1 саат мурун
News by CNBC TV18 on TradingView, 2026-10-18 — cnbctv:f99f7968e094b:0
FXLeaders
·
57 мүнөт мурун
Nasdaq and Dow Jones Futures Recover Ealy Monday Ahead of Meta, Tesla and SpaceX Earnings as Iran De-escalation Hopes Lift Sentiment
Bloomberg.com
·
2 саат мурун
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
Profile
Apeloa Pharmaceutical Co., Ltd., known as Apeloa, is a Chinese pharmaceutical manufacturer under Hengdian Group. The company is headquartered in Hengdian, Dongyang, Zhejiang, China. It was founded in 1989 and has been listed on the Shenzhen Stock Exchange since 9 May 1997. Apeloa provides contract development and manufacturing services and manufactures APIs and finished dosage forms; products span cardiovascular, anti-infective, psychiatric and oncology areas.
Apeloa has 7400 employees, 8 manufacturing sites and 3 R&D centers in Boston, Shanghai and Hengdian, covering flow chemistry, synthetic biology and biocatalysis, and peptide development. It has invested over USD20 million in flow chemistry over the past ten years in an effort to advance sustainable pharmaceutical manufacturing. In Boston, its 17,000-square-foot facility does R&D related to chemistry needs in drug development, including preclinical chemistry, scale-up production and new drug development.
Apeloa Pharmaceutical has successfully passed 20 U.S. FDA inspections since 2006. Wikipedia
About Apeloa Pharmaceutical Co Ltd